araag2/HINT huggingface dataset:
Clinical trial NCT00246662 (phase 1, status: completed)
Conditions: leukemia, lymphocytic, acute, leukemia, nonlymphocytic, acute, leukemia, myeloid, chronic, myelodysplastic syndromes
ICD codes: A87.2, K52.832, D72.111, C91.11, C91.12, C91.10, C92.11, C92.12, C92.21, C92.22, C92.10, C92.20, D46.9, D46.C, D46.Z
Drugs: vosaroxin
SMILES: CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O
Eligibility criteria:

        Inclusion:

          -  Able to understand and willing to sign a written informed consent document

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, 0r 2

          -  Received less than or equal to 3 induction/re-induction regimens for disease(s)
             defined by the protocol

          -  Must have relapsed or refractory leukemia for which no standard therapies are expected
             to result in a durable remission; patients who have not received prior treatment who
             have either refused or, in the opinion of the Investigator, are not able to tolerate,
             standard therapy may be included.

        Exclusion:

          -  Prior exposure to SNS-595 (vosaroxin)

          -  Pregnant or breastfeeding

          -  Women of childbearing potential or male partners of women of childbearing potential
             unwilling to use an approved, effective means of contraception according to the
             institution's standards

          -  Any evidence of active central nervous system (CNS) leukemia

          -  Any evidence of acute or chronic graft-versus-host disease

          -  Has active cancer (other than that which is defined by the inclusion criteria for this
             protocol), except for skin cancer (excluding melanoma)

          -  Laboratory values outside normal or reasonable reference range specified by the
             protocol

          -  Liver function and kidney function outside limits specified by the protocol

          -  Not yet recovered from side effects of previous cancer therapy

          -  Myocardial infarction, cerebrovascular accident/transient ischemic attack (TIA) or
             thromboembolic event (deep vein thrombosis or pulmonary embolus) within 6 months
             before the first SNS-595 dose

          -  Requires kidney dialysis (hemodialysis or peritoneal)

          -  Received an investigational agent within 14 days before Cycle 1, Day 1

          -  Prior pelvic radiation therapy or radiation to greater than or equal to 25% of bone
             marrow reserve (palliative radiation is not excluded as long as it does not exceed
             greater than or equal to 25% of bone marrow reserve)

          -  Any other medical (uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia), psychological, or social condition that, in the opinion
             of the Principal Investigator, would contraindicate the patient's participation in the
             clinical trial due to safety or compliance with study procedures
Clinical trial NCT00609011 (phase 1/phase 2, status: completed)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: mpc-6827 + temozolomide
SMILES: COC1=CC=C(C=C1)N(C)C1=NC(C)=NC2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven melanoma

          -  For subjects with brain metastases that require radiation, therapy must have been
             completed at least 4 weeks prior to Day 1 of Study Drug

          -  Have unresectable melanoma with measurable metastases

          -  Be a minimum of 4 weeks since prior surgical resection or major surgical procedure and
             a minimum of 2 weeks since chemotherapy/ biochemotherapy

          -  Performance score of Karnofsky ≥ 60%, or Eastern Cooperative Oncology Group (ECOG) ≤
             2, or WHO ≤ 2

          -  If steroids are needed, be on a stable or decreasing dose of steroids for at least 1
             week

        Exclusion Criteria:

          -  Hypersensitivity to Cremophor EL

          -  Have current/active intratumor hemorrhage by CT/MRI within 3 weeks prior to Day 1 of
             Study Drug confirmed by CT/MRI

          -  Have ocular melanoma

          -  Have primary intradural melanoma or leptomeningeal involvement

          -  Have cardiovascular disease (unstable angina or MI)

          -  Have cerebrovascular disease (stroke and/or TIA)

          -  Have uncontrolled hypertension

          -  Have a cardiac ejection fraction < 50%

          -  Have Troponin-I elevated above the normal range
Clinical trial NCT00482703 (phase 1/phase 2, status: completed)
Conditions: myeloid leukemia, chronic
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: dasatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Philadelphia chromosome positive or bcr-abl gene positive Chronic phase Chronic
             Myelogenous Leukemia (CML) subjects must have primary or acquired resistance to
             Imatinib mesylate or have intolerance of imatinib mesylate

          -  Performance status (general conditions) specified by the Eastern Cooperative Oncology
             Group: 0-2

          -  Men and women, ages 20 to 75

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 3 months after the
             study in such a manner that the risk of pregnancy is minimized

        Exclusion Criteria:

          -  Subjects who are eligible and willing to undergo transplantation at pre-study

          -  Women who are pregnant or breastfeeding

          -  Uncontrolled or significant cardiovascular disease

          -  History of significant bleeding disorder unrelated to CML

          -  Adequate hepatic function

          -  Adequate renal function

          -  Medication that increases bleeding risk

          -  Medication that changes heart rhythms

          -  Subjects who are compulsory detained for legal reasons or treatment of either a
             psychiatric or physical (e.g., infectious disease) illness must not be enrolled into
             this study
Clinical trial NCT01146808 (phase 1/phase 2, status: completed)
Conditions: hepatitis b, liver transplantation
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: adefovir dipivoxil and hepatitis b vaccination
SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Recipients who do not have evidence of hepatitis B surface antigen, regardless of
             HBcAb and HBsAb status, who:

               1. received liver transplantation with hepatitis B core antibody positive (and HBsAg
                  negative) grafts,

               2. received adefovir treatment post transplantation, and

               3. who have not reached the 18 month post transplantation time period.

        Exclusion Criteria:

          -  Recipients with hepatitis B surface antigen positivity prior to liver transplant.

          -  Grafts from hepatitis B surface antigen positive patients.

          -  Previous intolerance to ADV therapy

          -  Recipients with pre-transplant creatinine > 1.6 mg/dL

          -  Patients younger than 21 years of age

          -  Patients who are pregnant or breastfeeding
Clinical trial NCT00106353 (phase 1/phase 2, status: completed)
Conditions: adenocarcinoma, neoplasms
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: torisel
SMILES: OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
Eligibility criteria:

        Inclusion Criteria:

        Inclusion Criteria:

        Part 1 only:

        - Subjects with a histological diagnosis of advanced cancer (solid tumors or central
        nervous system [CNS] tumors) with disease that is recurrent or refractory to standard
        therapy or for whom standard therapy is not available (histological confirmation waived for
        brain stem gliomas and optic pathway tumors)

        Part 2 only:

          -  Subjects with histologically confirmed diagnosis of refractory or relapsed:
             Neuroblastoma, High-grade gliomas: glioblastoma multiforme, anaplastic astrocytomas,
             and other high-grade gliomas (histological confirmation waived for brain stem
             gliomas), Rhabdomyosarcoma.

          -  Measurable disease (for subjects with neuroblastoma, evaluable disease as determined
             by a positive metaiodobenzylguanidine (MIBG) scan will also be permitted).

        Exclusion Criteria:

        Exclusion Criteria:

          -  Subjects receiving enzyme-inducing anticonvulsants.

          -  Pulmonary hypertension or pneumonitis

          -  Active infection or serious intercurrent illness

          -  Other exclusions apply
Clinical trial NCT01211275 (phase 1/phase 2, status: completed)
Conditions: malignant pleural mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  histologically or cytologically diagnosed malignant mesothelioma

          -  age > 18 years

          -  Medically suitable for limited surgical intervention (pleural biopsies or limited
             pleurectomy)

          -  Measurable or evaluable disease is not required

          -  Ability to understand the study and give signed informed consent including the
             approval to accept a second thoracoscopic or surgical treatment after the third course

          -  No previous chemotherapy

          -  Radiotherapy is allowed when this is given for palliation, the interval is > 4 weeks,
             not more than 1/3 of the bone marrow capacity or all tumor is within the irradiation
             field.

          -  WHO performance status =< 2

          -  Adequate organ function as evidenced by the following peripheral blood counts or serum
             chemistries at study entry:

        Hematology:

          -  ANC=>1.5 x 109/L,

          -  Platelets=>150 x 109/L,

          -  Hemoglobin => 6,0 mmol/l

        Chemistry:

          -  total serum bilirubin < UNL;

          -  AST and ALT= < 2.5xUNL,

          -  AP < 5xUNL (unless bone metastases are present in the absence or any liver disease)

          -  Serum creatinine =< 2xUNL

        Exclusion Criteria:

          -  Active uncontrolled infection, severe cardiac dysfunction or uncorrectable bleeding
             tendency

          -  Previous successful pleurodesis

          -  Uncontrolled hypertension

          -  Symptomatic peripheral neuropathy => grade 2 according to NCIC CTC,version 3.0

          -  Presence of symptomatic CNS metastases

          -  Unstable peptic ulcer, unstable diabetes mellitus or other serious disabling condition

          -  Concomitant administration to any other experimental drugs under investigation

          -  Impaired renal function
Clinical trial NCT01068483 (phase 1, status: completed)
Conditions: breast cancer, colon cancer, ovarian cancer, endometrium cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bkm120
SMILES: FC(F)(F)C1=CC(=N)NC=C1C1=CC(=NC(=N1)N1CCOCC1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

        All patients:

          -  Histologically-confirmed advanced solid tumors

          -  Progressive, recurrent unresectable disease

          -  World Health Organization (WHO) Performance status ≤ 2

          -  No history of primary brain tumor or brain metastases

        MTD Expansion part:

          -  Histologically-confirmed advanced solid tumors

          -  Progressive, recurrent unresectable disease

          -  World Health Organization (WHO) Performance status ≤ 2

          -  No history of primary brain tumor; no brain metastases unless asymptomatic and
             clinically stable for ≥ 3 months

          -  Patients with genetic or molecular alteration of the PI3K pathway

        Exclusion Criteria:

          -  Prior treatment with a PI3K inhibitor

          -  History of or active major depressive episode, bipolar disorder, schizophrenia, or
             history of suicidal attempt or ideation

          -  No clinically manifest diabetes mellitus (treated and/or with clinical signs)

          -  No acute or chronic renal disease

          -  No acute or chronic liver disease

          -  No acute or chronic pancreatitis

          -  No unresolved diarrhea

          -  No impaired cardiac function or clinically significant cardiac diseases such as
             ventricular arrhythmia, congestive heart failure, uncontrolled hypertension

          -  No acute myocardial infarction or unstable angina pectoris within the past 3 months

          -  Not pregnant or nursing and fertile patients must use barrier contraceptives

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01309789 (phase 1, status: completed)
Conditions: lymphoma, large-cell, anaplastic, lymphoma, nk-cell, lymphoma, t-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: brentuximab vedotin, cyclophosphamide, brentuximab vedotin, prednisone, cyclophosphamide, doxorubicin, doxorubicin, prednisone, vincristine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-naive CD30-positive mature T-cell and NK-cell neoplasms, including systemic
             anaplastic large cell lymphoma

          -  Measurable disease of at least 1.5 cm

          -  ECOG performance status less than or equal to 2

        Exclusion Criteria:

          -  Known cerebral/meningeal disease, including history of progressive multifocal
             leukoencephalopathy

          -  Current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis
             fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell
             lymphoma, nasal type

          -  History of another primary malignancy that has not been in remission for at least 3
             years

          -  Left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial
             infarction within the past 12 months

          -  Viral, bacterial, or fungal infection within two weeks prior to the first dose of
             brentuximab vedotin

          -  Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
             positive status
Clinical trial NCT00714246 (phase 1, status: terminated)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bortezomib, carboplatin, docetaxel
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or
             stage IV NSCLC

          -  Age > 18 years

          -  ECOG PS < 2

          -  No prior chemotherapy

          -  Measurable disease

          -  Signed informed consent

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate hepatic function

        Exclusion Criteria:

          -  Untreated clinically active brain metastasis

          -  Radiotherapy within 2 weeks prior to initiation of protocol therapy

          -  Treatment with any investigational therapy within 4 weeks prior to enrollment

          -  History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma
             on situ of the cervix) within the last 5 years

          -  Patients in their reproductive age group should use an effective method of birth
             control. Men and women of childbearing potential must be willing to consent to using
             effective contraception while on treatment and for at least 3 months thereafter.
             Patients who are breast-feeding will be excluded from the study. Women of childbearing
             potential must have a negative pregnancy test.

          -  Major surgery within 3 weeks prior to enrollment

          -  Use of immunosuppressive agents including systemic corticosteroids within 4 weeks
             prior to enrollment (corticosteroids are permitted as physiological replacement
             therapy or as supportive care for nausea and emesis)

          -  Known history of Human immunodeficiency virus infection

          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the
             protocol per assessment by the investigator

          -  Concurrent serious medical infection or illness, or psychiatric illness likely to
             interfere with participation in this clinical study.

          -  History of known hypersensitivity to docetaxel or other drugs formulated with
             polysorbate 80, bortezomib, boron or mannitol

          -  Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any
             ECG abnormality at Screening has to be documented by the investigator as not medically
             relevant.
Clinical trial NCT00630110 (phase 1/phase 2, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, npi-2358 + docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC(C)(C)C1=C(\C=C2/NC(=O)\C(NC2=O)=C\C2=CC=CC=C2)N=CN1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and females ≥ 18 years of age

          -  ECOG performance status ≤ 1

          -  Pathologically or histologically confirmed advanced non-small cell lung cancer
             (unresectable Stage IIIb or IV) that has progressed after treatment with at least one
             chemotherapy regimen; measurable disease is not required for enrollment into this
             trial

          -  All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have
             resolved to Grade ≤ 2

          -  Signed informed consent

        Exclusion Criteria:

          -  Administration of certain chemotherapy, biological, immunotherapy, radiation therapy,
             surgery or investigational agent within specified time frames

          -  Significant cardiac history

          -  Prior treatment with tumor vascular disruptive agents

          -  Seizure disorder

          -  Brain metastases

          -  Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy

          -  Known infection with human immunodeficiency virus (HIV), or active hepatitis A, B, or
             C

          -  Patients with a prior hypersensitivity reaction to product components

          -  Pregnant or breast-feeding women.

          -  Concurrent, active second malignancy for which the patient is receiving therapy,
             excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Unwilling or unable to comply with procedures required in this protocol
Clinical trial NCT00539331 (phase 1, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: azd2171, paclitaxel, carboplatin
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Having histologically or cytologically confirmed NSCLC

          -  Patients with previously untreated advanced/metastatic (Stage IIIB/IV) or postsurgery
             recurrent NSCLC

          -  WHO performance status 0-1

        Exclusion Criteria:

          -  Untreated unstable brain or meningeal metastases

          -  Patient with inappropriate laboratory tests values

          -  Patient with poorly controlled hypertension